USPTO Examiner DIOP FATIMATA SAHRA - Art Unit 3783

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19010153ULTRA-MINIATURIZED WIRELESS-CONTROLLED PATCH TYPE DRUG PUMP AND ITS PREPARATION METHODJanuary 2025September 2025Allow901NoNo
18819570Medicament Delivery DeviceAugust 2024August 2025Allow1111NoNo
18507889MACROPOROUS SOLID HARD MICRONEEDLES WITH EMBEDDED PARTICULATE DRUGSNovember 2023December 2025Allow2550YesNo
18475015SYSTEMS AND METHODS FOR TREATING SKINSeptember 2023February 2026Allow2850NoNo
18159611Method for Operating a Benefit Agent Delivery System Comprising Microcells Having an Electrically Eroding Sealing LayerJanuary 2023February 2024Allow1210NoNo
17800893PLASMA GENERATION UNIT AND PLASMA TREATMENT APPARATUSAugust 2022February 2026Allow4210YesNo
17876626CANNULA AND OBTURATOR SYSTEM FOR MINIMALLY INVASIVE SURGERYJuly 2022March 2026Abandon4301NoNo
17642822APPARATUS AND METHOD FOR PHACOEMULSIFICATIONMarch 2022December 2025Abandon4510NoNo
17635601Cannula Comprising an Expandable Arrangement, Corresponding Cannula System and Method for Inserting at Least One Cannula into a SubjectFebruary 2022December 2025Abandon4610NoNo
17645394LOW DEAD SPACE NEEDLE HUBDecember 2021June 2024Abandon2910NoNo
17539471INTRAVASCULAR ULTRAVIOLET CATHETER AND METHODS FOR MAKING AND USING THE SAMEDecember 2021March 2026Abandon5221NoNo
17533782PERIPHERAL ARTERY BALLOON, A HYPO-TUBE FOR PREPARING A PERIPHERAL ARTERY BALLOON AND METHODS OF USE THEREOFNovember 2021October 2025Abandon4731NoNo
17610267PUNCTURE-ASSISTANCE TOOL, PUNCTURE DEVICE, AND PUNCTURE METHODNovember 2021August 2025Abandon4510NoNo
17513443SYSTEMS, APPARATUS, AND METHODS FOR ADMINISTERING A SUBSTANCEOctober 2021August 2025Abandon4620YesNo
17448763SYRINGE CAP, SYRINGE ASSEMBLY, AND PRE-FILLED SYRINGESeptember 2021February 2025Allow4110NoNo
17447786CATHETER NEEDLE ASSEMBLY WITH ENCLOSABLE NEEDLESeptember 2021October 2025Abandon4910NoNo
17446306DRUG DELIVERY DEVICE USING ULTRASONIC WAVEAugust 2021August 2023Abandon2410NoNo
17430911SAFE INSULIN NEEDLEAugust 2021June 2025Allow4610NoNo
17380791Pressure Waves for Vaccines, Genetic Modification and Medical TreatmentsJuly 2021February 2025Abandon4330NoNo
17369863ABSORPTION ENHANCING WEARABLE DEVICEJuly 2021April 2025Abandon4501NoNo
17369665CRADLE FOR AN INFUSION PUMP UNITJuly 2021December 2025Allow5420YesNo
17365316PREFILLED SYRINGE, SYRINGE ASSEMBLY, METHOD FOR MANUFACTURING PREFILLED SYRINGE, AND METHOD FOR INCREASING SURFACE AREAJuly 2021July 2023Allow2510YesNo
17364229ASSEMBLY FOR TRACHEAL INSTILLATION OF FLUID MEDICAMENTS IN INFANTS SUPPORTED BY NON-INVASIVE VENTILATIONJune 2021May 2025Abandon4710NoNo
17360694Rapidly Insertable Central Catheters Including Assemblies and Methods ThereofJune 2021December 2024Allow4121NoNo
17358504Rapidly Insertable Central Catheters Including Catheter Assemblies and Methods ThereofJune 2021July 2024Allow3721YesNo
17336263DYNAMIC MIXING AND DELIVERY SYSTEM FOR MIXING A THERAPEUTIC AGENT IN AN INJECTOR OR AUTOINJECTORJune 2021June 2024Allow3720NoNo
17295930SINGLE-USE CASSETTE ASSEMBLYMay 2021November 2025Allow5330YesNo
17295275METHODS AND DEVICES FOR TREATING A DISEASE WITH BIOTHERAPEUTICSMay 2021November 2025Abandon5430NoNo
17315873Hard-Packaged Safety Needle DeviceMay 2021June 2024Allow3821NoNo
17316403INFILTRATION CANNULA WITH DUAL ANGLE CONFIGURATIONMay 2021December 2023Allow3120YesNo
17241616SYSTEM FOR GRAVITY INCLUSION OF POWDER INTO A MEDICAL DELIVERY FLOW STREAMApril 2021February 2025Allow4641NoNo
17237909Rapidly Insertable Central Catheters Including Catheter Assemblies and Methods ThereofApril 2021October 2023Allow3011YesNo
17232594PERCUTANEOUS PULMONARY ARTERY DRAINAGE DEVICEApril 2021September 2024Abandon4101NoNo
17232265BABY/INFANT/TODDLER NASAL ASPIRATORApril 2021September 2024Abandon4110NoNo
17231075DEVICES AND METHODS FOR PROVIDING A BOLUS DOSE IN A MICROFLUIDIC CIRCUIT OF A PUMPApril 2021December 2024Allow4411NoNo
17228867THERMOFORMED MEDICAL SYRINGEApril 2021March 2024Allow3521YesNo
17276774MICRONEEDLE HAVING LAYERED STRUCTUREMarch 2021September 2024Abandon4210NoNo
17186989ADAPTIVE PRESSURE CONTROL FILTER FOR A FLUID MANAGEMENT SYSTEMFebruary 2021October 2025Allow5561NoNo
17180611BRAIN DRUG DELIVERY SYSTEM AND METHODFebruary 2021December 2023Abandon3411NoNo
17269016Cradle Unit for Delivery DeviceFebruary 2021August 2025Abandon5321NoNo
17248996Gas Management for Jetting CartridgeFebruary 2021September 2023Allow3100NoNo
17269131DEVICE COMPRISING MICRONEEDLES FOR COSMETIC FILLERS DELIVERYFebruary 2021March 2026Abandon6041NoNo
17171478MEDICAL DEVICE AND MEDICAL DEVICE SETFebruary 2021September 2024Abandon4421NoNo
17167526SYSTEM, DEVICE AND METHOD COMBINING BIOABSORBABLE FOAM WITH VACUUM TECHNOLOGY FOR NEOPLASTIC CYSTSFebruary 2021January 2025Allow4741YesNo
17165764CAPACITOR DETECTION FOR IV PUMP TUBE CALIBRATIONFebruary 2021March 2026Abandon6040NoNo
17127642DUAL CARTRIDGE CONTAINER APPLICATOR WITH NEEDLE PENETRATION CONNECTION TO TIPDecember 2020September 2024Allow4540NoNo
17123899MODULAR POWER AND CONNECTIVITY SYSTEM FOR INFUSION DEVICESDecember 2020February 2026Allow6071NoYes
17114137MACHINE LEARNING IN AN ARTIFICIAL PANCREASDecember 2020October 2025Allow5860YesNo
17114213MACHINE LEARNING IN AN ARTIFICIAL PANCREASDecember 2020August 2025Allow5650YesYes
16952433BENEFIT AGENT DELIVERY SYSTEM COMPRISING MICROCELLS HAVING AN ELECTRICALLY ERODING SEALING LAYERNovember 2020January 2024Allow3821NoNo
16951451STERILE CONNECTOR AND CANNULA ASSEMBLYNovember 2020January 2025Allow5030NoNo
17087583Fixture For Filling Hypodermic SyringesNovember 2020September 2023Allow3420NoNo
17051579IMPLANTABLE ACCESS DEVICE FOR ACCESSING THE VASCULAR SYSTEM OF A HUMAN OR ANIMAL BODY, PARTICULARLY SUBCUTANEOUSLY IMPLANTABLE ACCESS PORTOctober 2020February 2025Allow5240NoNo
17075423SYSTEMS AND METHODS FOR AUTOMATED INSULIN DELIVERY RESPONSE TO INACCURATE OR MISSED GLUCOSE VALUESOctober 2020October 2025Allow6050YesNo
17048007SHOCK ABSORBER FOR INJECTION DEVICESOctober 2020October 2024Allow4841YesNo
17046403Tool for Removing a Cap From a Medical Injection DeviceOctober 2020September 2024Allow4731NoNo
17045676ELECTROHYDRAULIC MICROJET DRUG DELIVERY DEVICEOctober 2020September 2023Allow3630NoNo
17035989WEARABLE AUTO-INJECTOR DEVICES AND METHODSSeptember 2020September 2024Abandon4830NoNo
17036217DRUG DELIVERY DEVICESeptember 2020September 2025Allow5970NoNo
17034821CANNULA FIXATION DEVICESeptember 2020March 2025Allow5340NoNo
17030336CARTRIDGE HOLDER AND MEDICINE INJECTION DEVICE COMPRSING THE SAMESeptember 2020August 2023Abandon3520NoNo
16968774IMPLANT CAPABLE OF RELEASING DRUG, AND MANUFACTURING AND USAGE METHODS THEREFORAugust 2020August 2025Abandon6031NoNo
16964419TUBE ASSEMBLY AND DISSOLVABLE TIPJuly 2020May 2024Abandon4610NoNo
16918471MEDICAL TUBEJuly 2020July 2024Abandon4920YesNo
16772565Therapeutic Agent Delivery Devices Having Integrated Pain Mitigation, and Methods for Using the SameJune 2020May 2024Abandon4721NoNo
16870574LARYNGEAL MASK AIRWAY FOR GASTROSCOPYMay 2020July 2024Allow5020NoNo
16741998CATHETER FLUSH DEVICE, SYSTEM, AND METHODSJanuary 2020June 2025Allow6041YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DIOP, FATIMATA SAHRA.

Strategic Value of Filing an Appeal

Total Appeal Filings
2
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
2
(100.0%)
Filing Benefit Percentile
10.9%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner DIOP, FATIMATA SAHRA - Prosecution Strategy Guide

Executive Summary

Examiner DIOP, FATIMATA SAHRA works in Art Unit 3783 and has examined 58 patent applications in our dataset. With an allowance rate of 56.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 46 months.

Allowance Patterns

Examiner DIOP, FATIMATA SAHRA's allowance rate of 56.9% places them in the 17% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by DIOP, FATIMATA SAHRA receive 2.53 office actions before reaching final disposition. This places the examiner in the 74% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by DIOP, FATIMATA SAHRA is 46 months. This places the examiner in the 11% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +40.2% benefit to allowance rate for applications examined by DIOP, FATIMATA SAHRA. This interview benefit is in the 87% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 21.1% of applications are subsequently allowed. This success rate is in the 24% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 30.2% of cases where such amendments are filed. This entry rate is in the 44% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 77% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 99% percentile among all examiners. Of these withdrawals, 50.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 75% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 46% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 6.1% of allowed cases (in the 83% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.